Amendment to Disclosure Schedule. The Disclosure Schedule to the Existing Credit Agreement are hereby amended in their entirety by inserting the Disclosure Schedule attached hereto as Exhibit A as a replacement thereto.
Amendment to Disclosure Schedule. 5. Section 4.01(a)(vii) of the Company Disclosure Schedule is hereby amended as provided in Annex I.
Amendment to Disclosure Schedule. At least five (5) Business Days prior to the anticipated Closing Date, the Seller Parties shall deliver to the Purchaser amendments to the Disclosure Schedule with respect to any event or matter which occurs after the Closing Date, if any, or confirm in writing that the Seller Parties make no amendments to the Disclosure Schedule. With respect to any amendment of the Disclosure Schedule (and the underlying events with respect to such disclosure), if such disclosure and underlying event would constitute or reasonably be expected to result in a Material Adverse Effect, the Purchaser shall have the right to terminate this Agreement. If the Purchaser does not exercise its right to terminate this Agreement within the five Business Day period preceding the anticipated Closing Date, the Purchaser shall be deemed to have waived such right with respect to such event or matter and the applicable representations shall be deemed to have been qualified as set forth in the amended Disclosure Schedule for purposes of satisfying the conditions to the Closing set forth in Section 6.2.
Amendment to Disclosure Schedule. Not later than January 15, 1997, the Cytec Parties, in their sole discretion, may elect to deliver to Purchaser one or more revised Schedules chosen by the Cytec Parties; provided, however, that no such Schedule shall include an addition of any matter that was not previously listed in another Schedule prior to the revision thereof (it being understood that the disclosure of such matter shall be as deemed appropriate by the Cytec Parties). The parties hereto agree that (i) the Disclosure Schedules shall thereafter be deemed to be amended and restated as set forth in such revised Disclosure Schedules and (ii) disclosure of any matter therein shall not be deemed an admission by Parent that such disclosure is material or constitutes a Material Adverse Effect.
Amendment to Disclosure Schedule. Schedule C-1 (the Disclosure Schedule) is hereby amended and restated to read as set forth on Schedule C-1 attached as Exhibit A to this Fifth Amendment, which supersedes and replaces in its entirety Schedule C and Schedule C-1 to the Note Purchase Agreement.
Amendment to Disclosure Schedule. Item 6.8 of the Disclosure Schedule is hereby amended by supplementing the table therein with the Subsidiaries set forth on Annex I hereto.
Amendment to Disclosure Schedule. (a) Annex D to the Disclosure Schedule is amended and restated to be in the form of Exhibit A to this Amendment.
Amendment to Disclosure Schedule. Section 4.1.2 of the Disclosure Schedule to the 2002 Loan Agreement is hereby deleted and replaced in its entirety with Exhibit A attached hereto.
Amendment to Disclosure Schedule. The following is hereby added to Section 4.4(a)(xiv) of the Disclosure Schedule, effective as of the initial delivery of the Disclosure Schedule: “Amended and Restated Stockholders Agreement, dated March 7, 2008 by and among MediNotes Corporation and the persons listed on the Schedules attached to the Stockholders Agreement.”
Amendment to Disclosure Schedule. At least five (5) Business Days prior to the anticipated First Milestone Closing Date, the Seller shall deliver to the Purchaser amendments to the Disclosure Schedule with respect to any event or matter which occurs after the Closing Date in respect of a First Milestone Closing Date Representation, if any, or confirm in writing that the Seller makes no amendments to the Disclosure Schedule in respect of a First Milestone Closing Date Representation. With respect to any amendment of the Disclosure Schedule (and the underlying events with respect to such disclosure), if such disclosure and underlying event would constitute or reasonably be expected to result in a Material Adverse effect, the Purchaser shall have the right to terminate this Agreement with respect to the Vifor Royalties. If the Purchaser does not exercise its right to terminate this Agreement with respect to the Vifor Royalties within the five (5) Business Day period preceding the anticipated First Milestone Closing Date, the Purchaser shall be deemed to have waived such right with respect to such event or matter and the First Milestone Closing Date Representation shall be deemed to have been qualified as set forth in the amended Disclosure Schedule for purposes of satisfying the conditions to the First Milestone Closing Date set forth in Section 6.5.
